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Abstract: UNLABELLED In this double-blind RCT, 4-month treatment with calcifediol compared with
vitamin D3 improved gait speed by 18 % among young postmenopausal women. Consistently, change
in 25(OH)D blood levels over time were significantly correlated with improvement in gait speed in these
women. No effect could be demonstrated for trunk sway. INTRODUCTION The aim of this study is to
test the effect of calcifediol compared with vitamin D3 on gait speed and trunk sway. METHODS Twenty
healthy postmenopausal women with an average 25(OH)D level of 13.2 ng/ml (SD = ±3.9) and a mean
age of 61.5 years (SD = ±7.2) were randomized to either 20 ฀g of calcifediol or 20 ฀g (800 IU) of vitamin
D3 per day in a double-blind manner. At baseline and at 4 months of follow-up, the same physiotherapist
blinded to treatment allocation tested 8-m gait speed and a body sway test battery (Sway star pitch and
roll angle plus velocity while walking 8 m, and standing on both legs on a hard and soft surface). All
analyses adjusted for baseline measurement, age, and body mass index. RESULTS Mean 25(OH)D levels
increased to 69.3 ng/ml (SD = ±9.5) in the calcifediol group and to 30.5 ng/ml (SD = ±5.0) in the vitamin
D3 group (p < 0.0001). Women receiving calcifediol compared with vitamin D3 had an 18 % greater
improvement in gait speed at 4-month follow-up (p = 0.046) adjusting for baseline gait speed, age, and
body mass index. Also, change in gait speed was significantly correlated with change in serum 25(OH)D
concentrations (r = 0.5; p = 0.04). Across three tests of trunk sway, there were no consistent differences
between groups and no significant correlation between change in 25(OH)D serum concentrations and
change in trunk sway. CONCLUSIONS Calcifediol improved gait speed in early postmenopausal women
compared with vitamin D3 and change in 25(OH)D level was moderately correlated with improvement
in gait speed. A benefit on trunk sway could not be demonstrated.
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Abstract
Summary In this double-blind RCT, 4-month treatment with
calcifediol compared with vitamin D3 improved gait speed by
18 % among young postmenopausal women. Consistently,
change in 25(OH)D blood levels over time were significantly
correlated with improvement in gait speed in these women.
No effect could be demonstrated for trunk sway.
Introduction The aim of this study is to test the effect of
calcifediol compared with vitamin D3 on gait speed and trunk
sway.
Methods Twenty healthy postmenopausal women with an
average 25(OH)D level of 13.2 ng/ml (SD=±3.9) and a mean
age of 61.5 years (SD=±7.2) were randomized to either 20 μg
of calcifediol or 20 μg (800 IU) of vitamin D3 per day in a
double-blind manner. At baseline and at 4 months of follow-
up, the same physiotherapist blinded to treatment allocation
tested 8-m gait speed and a body sway test battery (Sway star
pitch and roll angle plus velocity while walking 8 m, and
standing on both legs on a hard and soft surface). All analyses
adjusted for baseline measurement, age, and bodymass index.
Results Mean 25(OH)D levels increased to 69.3 ng/ml (SD=
±9.5) in the calcifediol group and to 30.5 ng/ml (SD=±5.0) in
the vitamin D3 group (p<0.0001). Women receiving
calcifediol compared with vitamin D3 had an 18 % greater
improvement in gait speed at 4-month follow-up (p=0.046)
adjusting for baseline gait speed, age, and body mass index.
Also, change in gait speed was significantly correlated with
change in serum 25(OH)D concentrations (r=0.5; p=0.04).
Across three tests of trunk sway, there were no consistent
differences between groups and no significant correlation
between change in 25(OH)D serum concentrations and
change in trunk sway.
Conclusions Calcifediol improved gait speed in early post-
menopausal women compared with vitamin D3 and change in
25(OH)D level was moderately correlated with improvement
in gait speed. A benefit on trunk sway could not be
demonstrated.
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Introduction
Gait speed assessment among older patients has been pro-
posed as a key diagnostic tool [1] for the prediction of dis-
ability [2] and loss of autonomy [3] and its association with
accelerated progression of several age-related chronic dis-
eases, such as falls and fractures, as well mortality risk [4].
Several cross-sectional studies found an association be-
tween higher 25(OH)D level and greater gait speed [5–10].
However, a recent trial-level meta-analysis of clinical trials
could not confirm this association based on limited data from
three trials that tested gait speed as an endpoint [11]. Of the
three trials pooled by Muir and Montero-Odasso, one provid-
ed 300,000 IU vitamin D3 [12], one 20 IU calcitriol [13], and
one 400 IU vitamin D3 in combination with 800 mg calcium
[14], and only the latter demonstrated a significant benefit on
gait speed. The samemeta-analysis demonstrated a significant
reduction of postural sway across three trials, which individ-
ually showed a nonsignificant benefit (standardized mean
difference of −0.20; 95 % confidence interval (CI)=−0.39 to
−0.01): one provided 400 IU vitamin D3 in combination with
800 mg calcium daily [14], one 600,000 IU vitamin D2 once
per year [15], and one 800 IU vitamin D3 plus 1000 mg of
calcium daily [16]. With respect to their analyses by dose, the
authors concluded that optimal benefits are achieved with
daily doses of 800 to 1000 IU, while lower doses or a large
annual dose of vitamin D were less effective with respect to
muscle strength and balance [11].
Mechanistically, several lines of evidence support a possi-
ble role of vitamin D supplementation in gait speed and trunk
sway among individuals at risk of vitamin D deficiency. First,
the vitamin D receptor (VDR) is expressed in human muscle
tissue [17, 18], although this was questioned recently [19].
Second, VDR activation may promote de novo protein syn-
thesis in muscle [20], as recently confirmed in a controlled
clinical trial among 21 mobility-limited women aged 65 and
older [21]. Third, Mice lacking the VDR show a skeletal
muscle phenotype with smaller and variable muscle fibers
and persistence of immature muscle gene expression during
adult life [22, 23]. Fourth, proximal muscle weakness is a
prominent feature of the clinical syndrome of vitamin D defi-
ciency [24]. Clinical findings in vitamin D deficiency myopa-
thy include proximal muscle weakness, diffuse muscle pain,
and gait impairments such as waddling way of walking [25].
To our knowledge, no trial to date has tested whether
shifting individuals to a higher 25(OH)D serum concentration
beyond what would be achieved with the current standard of
800 IU vitamin D per day has an effect on gait speed or
balance. Therefore, the goal of this trial was to assess the
effect of calcifediol, known to be two to three times more
potent than vitamin D3 [26, 27], compared with 800 IU vita-




Twenty white postmenopausal women 50–70 years of age and
in good general health were recruited through newspaper
advertisements for this clinical trial and randomized to receive
oral supplementation of either 20 μg of calcifediol or 20 μg
(800 IU) of vitamin D3 per day. Other inclusion criteria were
serum 25 (OH)D level between 8 and 24 ng/ml (20 to
60 nmol/l), body mass index between 18 and 29 kg/m2, and
ability to give informed consent. Exclusion criteria consisted
of medical contraindications to vitamin D supplements, med-
ical conditions, or medication use that would alter pharmaco-
kinetics of study products or otherwise interfere with the
study. All subjects were recruited at the Centre on Aging
and Mobility, University Hospital Zurich, Switzerland. This
study was approved by the Zurich Cantonal Ethical Commit-
tee and Swiss Medic. Written informed consent was obtained
from all study participants. The trial has been registered at the
international trial registry (NCT00718276). The primary trial
findings with respect to pharmacokinetics, lower extremity
strength, blood pressure, and markers of innate immunity are
published elsewhere [28, 29].
Treatment arms
The original study design envisioned two regimens for
calcifediol (n=10) and vitamin D3 treatment (n=10). For each
treatment strategy, five participants took 20 μg (800 IU) daily
and another five participants took 140 μg (5600 IU) once a
week. As in the earlier analysis, effects of daily and weekly
treatment regimens were similar [28], and we combined daily
and weekly data for each of the two treatment groups:
calcifediol (daily or weekly) and vitamin D3 (daily or weekly).
Outcome measures
Study participants attended a screening visit and 14 clinical
visits during a 4-month follow-up period with laboratory
measures of 25(OH)D taken at each visit as described earlier
[28, 29]. Gait speed (normal pace) and trunk sway measure-
ments were made at baseline (visit 2) and at 4-month follow-
up visit (visit 15). For trunk sway testing, we used the
SwayStar™ system [30] which consists of two angular veloc-
ity transducers fixed on a belt strapped around the waist at the
level of the lumbar spine [31]. For trunk sway testing, each
participant performed an 8-m walk, a two-legged stance on a
firm surface, and a two-legged stance on a soft surface. For
each of the three trunk sway tests, we documented pitch and
roll trunk angular displacement and pitch and roll angular
velocity. The time that participants took to complete their 8-
m walk was used to calculate gait speed (meter per seconds).
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Subjects, investigators, study physician, and nurses were
aware of treatment regimen (daily or weekly), but blinded
with regard to type of treatment (calcifediol or vitamin D3).
The physiotherapist who assessed gait speed and trunk sway
was blinded to both regimen and type of treatment. Two
participants of the calcifediol group did not have trunk sway
and gait speed measured at baseline and follow-up, which is
why our endpoint analyses compares 10women in the vitamin
D3 group to 8 women in the calcifediol group. All other
functional measures (Timed up and go, knee extensor and
flexor strength, repeated sit-to-stand) and laboratory values
were available in all 20 women and are reported elsewhere
[28]. In brief, serum 25(OH)D concentration was assessed by
means of a sensitive and selective assay based on liquid
chromatography coupled to tandem mass spectrometry detec-
tion (HPLC-MS/MS), which selectively measures 25(OH)D3
and was validated in an international NISTcomparison (www.
nist.gov; available from the authors). 1,25-hydroxyvitamin D
was assessed by a radioimmunoassay. Intact PTH was
m e a s u r e d i n EDTA b l o o d b y m e a n s o f a n
electrochemiluminescence immune assay [32]. Serum
calcium levels and urinary calcium excretion (calcium/
creatinine ration in spot urine) were assessed with automated
assays at the Institute for Clinical Chemistry at the University
Hospital in Zurich. For all laboratory analyses, we used the
two measurements (at baseline and 4 months of follow-up)
that coincide with the gait speed and trunk sway
measurements.
Statistical analyses
All statistical analyses were based on intent to treat. Compa-
rability of the treatment groups with respect to important
demographic characteristics, baseline serum levels of
25(OH)D, gait speed, and trunk sway characteristics was
assessed by a two-sample t test. Variables whose distributions
grossly deviated from normal were log-transformed to comply
with assumptions of the t test. To evaluate association between
gait speed and balance measurements and serum 25(OH)D
levels, differences between follow-up and baseline measure-
ments were calculated for gait speed and each of the balance
measurements. Then, Pearson’s correlations between each of
these differences and a similarly calculated difference between
the follow-up and baseline concentrations of 25(OH)D were
evaluated. Linear regression models were run to evaluate the
effects of vitamin D3 and calcifediol supplementation on gait
speed and trunk sway. Each model adjusted for age, BMI, and
baseline values of the respective outcome variables. Since
angular displacement and angular velocity measurements
had highly skewed distributions, these variables were log-
transformed to improve their normality and fulfill modeling
assumptions. The modeling was done on the logarithmic
scale, and the results were converted back to their original
scale. Since the functional endpoints were considered second-
ary endpoints, we did not adjust for multiple testing. However,
caution is appropriate when interpreting the p values for our
secondary outcomes.
All statistical analyses were performed using SAS v.9.3
statistical software (Copyright© SAS Institute, Cary, NC,
USA) at α=0.05 (two-sided) level of statistical significance.
Randomization was computer generated by an independent
statistician.
Results
Table 1 summarizes baseline characteristics of the study pop-
ulation. Groups randomized for treatment with vitamin D3 and
calcifediol were comparable with respect to all investigated
characteristics. Mean age, 25(OH)D level, and BMI were
slightly lower in the calcifediol group; however, none of the
group differences reached statistical significance (Table 1).
Serum 25(OH)D3 levels, serum 1,25-dihydroxyvitamin D,
serum intact PTH
Mean 25(OH)D3 levels increased from 12.3 to 69.3 ng/ml
(SD=±9.5) in the calcifediol group and from 14.2 to
30.5 ng/ml (SD=±5.0) in the vitamin D3 group (p<0.0001).
Serum 25(OH)D levels shifted to above 30 ng/ml in all
participants of the calcifediol group, while in the vitamin D3
group, about 50 % of participants remained below this thresh-
old at 4 months of follow-up. Both treatments resulted in an
increase in 1,25(OH)2D levels, but this increase was more
pronounced with calcifediol. Average circulating
1,25(OH)2D rose by 19.5 pg/ml in the calcifediol group and
by 2.5 pg/ml in the vitamin D3 group (p=0.004). Circulating
concentrations of intact PTH declined in both groups, but the
decreases in the two groups did not differ significantly. Aver-
age circulating intact PTH declined by 20.2 pg/ml in the
calcifediol group and by 3.2 pg/ml in the vitamin D3 group
(p=0.09).
Mean serum calcium levels did not differ by group at
4 months of follow-up (2.27 for vitamin D3 and 2.27 for
calcifediol; p value=0.97; reference range 2.19 to
2.60 mmol/l) [28]. Similarly, at 4-month follow-up, there
was no significant difference in urinary calcium excretion
between groups assessed as the calcium/creatinine ratio in
spot urine (0.33 for vitamin D3 and 0.33 for calcifediol;
p value=0.98; reference range 0.1–0.5 mmol/mmol) [28].
Gait speed
Women receiving calcifediol compared with vitamin D3 had a
16 % greater improvement in gait speed at 4-month follow-up
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(p=0.03) adjusting for baseline gait speed (minimally adjusted
model). This difference was maintained at 18 % (p=0.046)
after adjustment for age and body mass index in addition to
baseline gait speed (Table 2, Fig. 1). Further, change in gait
speed was correlated with change in serum 25-
hydroxyvitamin D concentrations (r=0.50; p=0.04, Table 3,
Fig. 2a) and inversely correlated with change in intact PTH
levels (r=−0.42; p=0.08, Fig. 2b), significant for change in
25(OH)D and approaching significance for change in intact
PTH level . Change in gait speed was not correlated with
change in 1,25(OH)2D (r=0.19; p=0.46).tgrouptgroup
Notably, for change in 25(OH)D serum concentration,
there was no overlap between the two treatment groups in
Fig. 2a. Also, in the calcifediol group alone the line was flat,
suggesting that all participants were above the threshold need-
ed for gait speed performance. For the correlation plot on
change in gait speed with change in serum intact PTH con-
centrations (Fig. 2b), there was an overlap between treatment
groups with a suggestion that overall and within treatment
groups a greater suppression of intact PTH levels was associ-
ated with better gait speed performance.
As an exploratory analysis due to the small sample size, we
added change in 25(OH)D level and change in PTH level to
our minimally adjusted model of the effect of treatment
(calcifediol versus vitamin D3) on gait speed at 4-month
follow-up to assess which of the two changes attenuates the
treatment effect. In the minimally adjusted model, controlling
for baseline gait speed only, women receiving calcifediol
compared with vitamin D3 had a 16 % greater improvement
in gait speed at 4-month follow-up (p=0.03). Adding change
in 25(OH)D level (follow-up minus baseline) to this model,
the treatment effect was not attenuated and change in
25(OH)D level had no independent effect on gait speed at 4-
month follow-up (p=0.99). Adding change in intact PTH
level (follow-up minus baseline) to the model, the treatment
effect was attenuated from 16 to 10.9 % and change in PTH
level approached significance (p=0.11). These exploratory
findings, taking the limitation of a small sample size into
account, support parathyroid hormone response as a mediator
of the treatment effect, rather than change in 25(OH)D level.
Trunk sway test battery
Across three tests of trunk sway (walking 8 m, standing on
two legs on firm surface, standing on two legs on soft surface),
there were no consistent differences between groups in the
Table 1 Baseline characteristics
of the study population
All variables are presented as
mean (SD); p values are based on
two-sample t test. For the t tests
age, BMIs were compared on
their natural scales, and the rest of
the variables were log-
transformed to bring their distri-
butions closer to normality. In the
vitamin D3 group, all measure-
ments are based on 10 partici-
pants. In the calcifediol group,
gait speed and trunk sway are
based on eight participants only.
Both treatment groups are com-
parable with respect to all baseline
assessments





Age (years) 63.5 (7.8) 59.5 (6.3) 0.22
BMI (kg/m2) 25.5 (3.4) 23.2 (3.2) 0.15
25(OH)D (ng/ml) 14.2 (3.6) 12.3 (4.1) 0.20
1,25(OH)2D (pg/ml) 38.6 (12.1) 33.0 (13.6) 0.36
Intact PTH (pg/ml) 54.9 (10.7) 63.2 (16.4) 0.19
Serum calcium (mmol/l) 2.27 (0.08) 2.26 (0.07) 0.71
Urinary calcium excretion (calcium/creatinine ratio) 0.25 (0.15) 0.28 (0.18) 0.28
Gait speed—8-m walk (m/s) 1.11 (0.22) 1.08 (0.08) 0.83
Trunk sway 8-m walk
Roll angular displacement (deg) 1.16 (0.98) 0.98 (0.94) 0.91
Roll angular velocity (deg/s) 0.82 (0.34) 0.64 (0.51) 0.18
Pitch angular displacement (deg) 3.33 (1.47) 4.99 (4.39) 0.60
Pitch angular velocity, (deg/s) 1.01 (0.79) 0.96 (0.99) 0.36
Standing on two legs on firm surface
Roll angular displacement (deg) 0.13 (0.13) 0.11 (0.05) 0.57
Roll angular velocity (deg/s) 0.008 (0.005) 0.009 (0.006) 0.66
Pitch angular displacement (deg) 0.45 (0.39) 0.43 (0.35) 0.76
Pitch angular velocity (deg/s) 0.04 (0.03) 0.02 (0.01) 0.98
Standing on two legs on soft surface
Roll angular displacement (deg) 0.28 (0.13) 0.33 (0.31) 0.46
Roll angular velocity (deg/s) 0.02 (0.01) 0.03 (0.04) 0.70
Pitch angular displacement (deg) 0.71 (0.61) 0.67 (0.64) 0.80
Pitch angular velocity (deg/s) 0.05 (0.03) 0.04 (0.04) 0.27
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analyses that adjusted for baseline sway only (data not
shown). In the fully adjusted analyses presented in Table 2,
only roll angular velocity standing on two legs on a firm
surface was 132 % greater in the calcifediol group compared
with the vitamin D3 group (p=0.04).
Consistent with the overall lack of between treatment
group differences for trunk sway, we did not find a correlation
between change in 25(OH)D level and change in any of the
trunk sway measures (Table 3). Similarly, there was no corre-
lation significant correlation between change in 1,25(OH)2D
level and change in any of the trunk sway measures (data not
shown).
Change in PTH was significantly and inversely correlated
with change in pitch angular displacement during 8-m walk
Table 2 Effect of treatment (calcifediol versus vitamin D3) on gait speed and trunk sway





Gait speed (m/s) 1.02 (0.91–1.13) 1.20 (1.08–1.33) 0.18 (18 %) 0.046
Trunk sway test battery
8-m walk
Roll angular displacement (deg) 0.72 (0.26–1.99) 0.31 (0.10–1.00) −0.41 (56 %) 0.30
Roll angular velocity (deg/s) 0.39 (0.24–0.63) 0.69 (0.40–1.19) 0.30 (77 %) 0.13
Pitch angular displacement (deg) 2.43 (1.22–4.86) 3.84 (1.75–8.39) 1.40 (58 %) 0.39
Pitch angular velocity, deg./s. 0.62 (0.21–1.85) 0.35 (0.10–1.20) −0.27 (44 %) 0.49
Standing on two legs on firm surface
Roll angular displacement (deg) 0.07 (0.03–0.15) 0.07 (0.03–0.16) 0.0 (0 %) 0.99
Roll angular velocity (deg/s) 0.005 (0.003–0.008) 0.012 (0.007–0.021) 0.007 (132 %) 0.04
Pitch angular displacement (deg) 0.27 (0.12–0.57) 0.45 (0.19–1.07) 0.18 (69 %) 0.40
Pitch angular velocity (deg/s) 0.03 (0.01–0.07) 0.04 (0.02–0.09) 0.01 (19 %) 0.77
Standing on two legs on soft surface
Roll angular displacement (deg) 0.16 (0.04–0.58) 0.09 (0.02–0.41) −0.06 (40 %) 0.60
Roll angular velocity (deg/s) 0.013 (0.004–0.042) 0.008 (0.002–0.031) −0.005 (38 %) 0.60
Pitch angular displacement (deg) 0.44 (0.31–0.62) 0.31 (0.21–0.46) −0.12 (29 %) 0.21
Pitch angular velocity (deg/s) 0.02 (0.01–0.05) 0.03 (0.01–0.10) 0.01 (72 %) 0.45
Table 2 presents least square means (95 % confidence interval) by treatment group and the difference between treatment groups as a mean difference and
percent difference. Women receiving calcifediol compared with vitamin D3 had an 18 % greater improvement in gait speed at 4-month follow-up (p=
0.046) adjusting for baseline gait speed, age, and bodymass index. Across three tests of trunk sway, there were no consistent differences between groups;
























p = 0.83 p = 0.046 
Fig. 1 Gait speed by treatment
group at baseline and at 4-month
follow-up. Baseline box plots
show the unadjusted means for
gait speed. The 4-months follow-
up box plots show the least square
means of gait speed adjusted for
baseline gait speed, age, and BMI.
Whiskers show standard errors. At
baseline, mean gait speed did not
differ significantly between
groups (p=0.83). At 4-month
follow-up, calcifediol treatment
contributed to an 18 % increase in
gait speed compared with vitamin
D3 (p=0.046)
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(r=−0.51, p=0.03) and moderately positively correlated with
roll angular displacement when standing on firm surface (r=
0.48, p=0.04). Another negative correlation between PTH
change and change in roll angular velocity during 8-m walk
approached significance (r=−0.41, p=0.09).
Discussion
In this clinical trial, calcifediol improved gait speed by 18% in
young postmenopausal women compared with 800 IU vita-
min D3 and within 4 months of treatment. Notably, we also
documented a significant positive correlation between change
in 25(OH)D level and change in gait speed, as well as an
inverse correlation between change in intact PTH level and
change in gait speed approaching significance. In contrast, our
detailed assessment of trunk sway while walking or standing
did not change differentially with treatment or with a greater
change in 25(OH)D status over time. Our study supports the
concept that calcifediol may be more potent than standard
vitamin D3 not only with respect to change in 25(OH)D status
but also with respect to gait speed improvement in young
postmenopausal women.
In this study, calcifediol treatment shifted all participants to
a mean of 69.3 ng/ml at 4-month follow-up compared with a
mean of 30.5 ng/ml in women receiving 800 IU vitamin D3
per day. The change over time assessed in 14 visits among all
participants has been reported earlier showing that already at
day 35, all participants in the calcifediol group reached the
threshold of 30 ng/ml [28]. Notably, within the range of
change in 25(OH)D achieved in the calcifediol group, the
response to change in gait speed was flat suggesting that gait
speed improvement had leveled off in the higher 25(OH)D
level—reached by all participant of the calcifediol group. Our
findings are supported by several large cross-sectional studies,
where gait speed continued to increase to the upper end of the
respective reference range in 25(OH)D concentrations of the
individual studies. In a large population-based study including
the ambulatory US population aged 60 to ≥90 years of age
Table 3 Correlations between change in serum 25(OH)D concentration—and change in gait speed/trunk sway over 4-month follow-up
Change gait speed and change in trunk sway
(follow-up—baseline)
Change in serum concentration of 25(OH)D
(follow-up—baseline)
Change in serum concentration of intact PTH
(follow-up—baseline)
r p r p
Gait speed (m/s) 0.50 0.04 − 0.42 0.08
Trunk sway
8-m walk
Roll angular displacement (deg) 0.23 0.36 −0.14 0.57
Roll angular velocity (deg/s) 0.19 0.45 −0.41 0.09
Pitch angular displacement (deg) 0.11 0.67 −0.51 0.03
Pitch angular velocity (deg/s) −0.05 0.85 0.02 0.93
Standing on two legs on firm surface
Roll angular displacement (deg) −0.05 0.84 0.48 0.04
Roll angular velocity (deg/s) 0.08 0.76 0.06 0.81
Pitch angular displacement (deg) −0.01 0.97 −0.12 0.63
Pitch angular velocity (deg/s) 0.34 0.17 −0.15 0.54
Standing on two legs on soft surface
Roll angular displacement (deg) −0.20 0.42 0.17 0.51
Roll angular velocity (deg/s) −0.24 0.34 0.27 0.29
Pitch angular displacement (deg) −0.11 0.68 0.05 0.83
Pitch angular velocity (deg/s) 0.11 0.66 −0.10 0.69
Changes are calculated based on difference between the 4-month follow-up value minus baseline value. All correlations listed for gait speed and trunk
sway measurements refer to the same change in the serum 25(OH)D concentrations/intact PTH concentrations. Only change in gait speed was
significantly correlated with change in serum 25-hydroxyvitamin D concentrations (r=0.50; p=0.04), and otherwise, none of the trunk sway measures
reached or approached significance for the correlation with change in 25(OH)D concentrations. Individual measurements for change in gait speed by
change in 25(OH)D serum concentrations are shown in Fig. 2a. Change in PTH concentration was inversely correlated with change in gait speed and
approached significance (r=−0.42; p=0.08; see Fig. 2b). Change in PTH was significantly and inversely correlated with change in pitch angular
displacement during 8-m walk (r=−0.51, p=0.03) and moderately positively correlated with roll angular displacement when standing on firm surface
(r=0.48, p=0.04). Another negative correlation between PTH change and change in roll angular velocity during 8-m walk approached significance
(r=−0.41, p=0.09)
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(NHANES III) [6], gait speed continued to increase through-
out the NHANES III reference range of 25(OH)D (9 to
37.6 ng/ml) with most of the improvement occurring in
25(OH)D levels going from 9 to approximately 16 ng/ml.
Compared with the lowest quintile of 25(OH)D, the highest
quintile showed an average improvement by 5.6 % in gait
speed (test for trend: p<0.001). A similar association was seen
in 2694 community-dwelling seniors age 65 and older from
Italy. Compared to the lowest quintile of 25(OH)D, the highest
quintile showed an average improvement in gait speed by
21 % in both men and women (test for trend: p<0.0001) [7].
Similarly, in the EPIDOS study, both usual and fast walking
speed was associated with 25(OH)D status. Compared with
seniors reaching a 25(OH)D serum level of greater than
30 ng/ml, any lower 25(OH)D range (20 to 30 ng/ml; 10 to
20 ng/ml; <10 ng/ml) was associated with a significant 2.8 to
7.0-fold increased odds of being in the worst quintile of
walking speed for both usual and fast walking speed, with
the most extreme risk observed among seniors with 25(OH)D
levels <10 ng/ml [8]. Also, in the Health ABC study, adjusting
for demographic factors, site, and season, baseline 25(OH)D
was associated with 20 and 400 m gait speed at baseline and 2
and 4 years later, and participants with baseline 25(OH)D
<20 ng/ml had slower gait speed at each time point compared
with seniors who had 25(OH)D ≥30 ng/ml (p<0.01) [33].
In our detailed assessment of trunk sway while walking or
standing (firm and soft surface), calcifediol versus standard
vitamin D3 did not improve trunk sway. Also, we did not find
a significant correlation between change in 25(OH)D level
and change of any trunk sway measure while walking or
standing over time. There are several possible speculations
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aFig. 2 Correlation between
change in gait speed and change in
25(OH)D and change in intact PTH
level. a Correlation between
change in 25(OH)D serum
concentration and change in gait
speed (baseline—month 4).
Change in gait speed was
significantly correlated with change
in serum 25-hydroxyvitamin D
concentrations (r=0.50; p=0.04).
Correlation coefficient is based on
Pearson correlation. There was no
overlap between the two treatment
groups (indicated with different
symbols: open circle = vitamin D3
group; filled square = calcifediol).
Notably, within the range of change
in 25(OH)D achieved in the
calcifediol group, the response to
change in gait speed was flat
suggesting that gait speed
improvement had leveled off in the
higher 25(OH)D level—reached by
all participant of the calcifediol
group. b Correlation between
change in intact PTH
concentrations and change in gait
speed (baseline—month 4).
Change in gait speed was
significantly correlated with change
in serum intact PTH concentrations
(r=−0.42; p=0.08). Correlation
coefficient is based on Pearson
correlation. For the correlation plot
on change in gait speed with
change in serum intact PTH
concentrations, there was an
overlap between treatment groups
(indicated with different symbols:
open circle = vitamin D3 group;
filled square = calcifediol)
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analysis of Muir and Montero-Odasso [11]. One speculation
could be that we selected a relatively healthy and young group
of postmenopausal women with a mean age below 65 years
where trunk sway may not have been impaired to a degree
where vitamin D supplementation mattered enough to be
detected within the 4-month follow-up or the small study
sample we investigated. The pooled analysis of Muir included
seniors at higher age and, in part, pre-frail with a history of a
fall [11]. Using the same SwayStar technology in an earlier
trial among 64 institutionalized elderly women treated with
800 IU vitamin D plus 1200 mg of calcium versus calcium
alone, we observed a 60 % reduction in the rate of falls in the
vitamin D group, and up to 22 % of the treatment effect was
explained by a change in postural balance and up to 14 % by
dynamic balance [34]. Alternatively, there could be different
25(OH)D thresholds for different aspects of function as sug-
gested by Houston and colleagues in the Health ABC study
[9]. Within this concept, the 25(OH)D threshold for optimal
trunk sway may be lower than that for gait speed [11], which
allowed us to detect a groups difference for gait speed but not
for trunk sway as the control group received 800 IU vitamin
D3, which may be a sufficient dose for trunk sway improve-
ment. Finally, our sample may have been too small to detect
small changes in trunk sway.
Despite its small sample size, our exploratory analysis
provides some support to the concept that parathyroid hor-
mone suppression may improve gait speed independent of a
rise in 25(OH)D level, as described by Sambrook and col-
leagues for fall risk [35]. A possible independent role of
parathyroid hormone is also suggested in a small study of 18
asymptomatic patients (mean age 66 years) with primary
hyperparathyroidism who were found to have a 52 % lower
gait speed compared with healthy age-matched normative
values despite their replete vitamin D status (mean 25(OH)D
serum concentrations were 44 ng/ml) [36]. Further, our trial
found that parathyroid hormone response is a correlate with
gait speed improvement (r=−0.42; p=0.08) and few trunk
sway measures.
Our trial has several strengths despite its small size. The
trial was sufficiently powered to detect a treatment effect for
gait speed. Further, the improvement in gait speed by
calcifediol is consistent with and is an extension of the find-
ings of the earlier paper from the same trial, where we docu-
mented a significant 17 % improvement for knee extensor
strength with calcifediol versus vitamin D3 and nonsignificant
improvements for knee flexor strength (4 %), for functional
mobility (timed up and go test; 8 %), and for reaction time
(repeated sit-to-stand test; 12 %) [28].
In conclusion, our results support calcifediol over standard
vitamin D as a potential strategy in improving gait speed in
young postmenopausal women at risk for vitamin D deficien-
cy. Given the small size of our trial, our data need confirma-
tion in a larger clinical trial and more research is needed to
identify the desirable 25(OH)D threshold for gait speed versus
trunk sway in healthy postmenopausal women.
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